• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 08, 2020 at 12:12: AM
via Gilead's Kite Pharma is waiting for phase 3 data that show its Yescarta can help previously treated diffuse large B-cell lymphoma (DLBCL) patients earlier in their treatment course. But in the meantime, it’s trumpeting phase 2 data in newly diagnosed lymphoma patients that it thinks bode well for its forthcoming results.

article source
 

<



Similar threads

cafead
ASH: Bristol Myers bolsters Breyanzi&#039;s case in earlier lymphoma amid clash with Gilead
Replies
0
Views
263
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Bristol Myers&#039; Breyanzi, Gilead&#039;s Yescarta lock horns in race to move CAR-T...
Replies
0
Views
275
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Gilead touts &#039;astounding&#039; Yescarta survival results at 3 years
Replies
0
Views
189
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits
Replies
0
Views
423
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah
Replies
0
Views
259
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote